Understanding the immune response to disease, injury and therapy can have a substantial impact on healthcare. Cellintec will provide a novel, scalable, economic approach using the DNA methylation status of immune cells to derive quantitative, easily standardized immune cell profiles that can be tracked through time and compared between patients and across clinical sites. This capability will enable healthcare providers to choose a cancer treatment based on the level of a patient’s immune suppression, cohort patients for clinical trials based on their immune status, assess an individual’s responsiveness to treatments (especially immune therapies), capture and characterize an autoimmune or allergic response, and monitor a person’s general immune health.
Infants can be born with diseases, such as neonatal opioid addiction, but they cannot voice their discomfort directly to their parents or medical practitioners. In 2014, 32,000 babies were born with neonatal opioid addiction. Testing for neonatal opioid withdrawal is very easy through urine or meconium (a baby's first bowel movement.) This technology aims to provide a non-invasive diagnose of this disorder through use of frequency analysis. Furthermore, they also aim to use this device to diagnose other infant developmental disorders.
TechStyle Materials is developing a range of construction materials and membranes that increase the energy efficiency, the comfort, and the durability of buildings. These materials use evaporation and selective vapor permeability to passively draw heat away from the the interior of structures and buildings. By hierarchically controlling the membrane composition and morphology, the membrane can be adjusted to passively cool buildings in a wide range of climate conditions - thus reducing the the energy demand for air conditioning within the building.